GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Myriad Genetics Inc (LTS:0K3W) » Definitions » Cyclically Adjusted Price-to-FCF

Myriad Genetics (LTS:0K3W) Cyclically Adjusted Price-to-FCF : 31.35 (As of Dec. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Myriad Genetics Cyclically Adjusted Price-to-FCF?

As of today (2024-12-11), Myriad Genetics's current share price is $15.3599. Myriad Genetics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 was $0.49. Myriad Genetics's Cyclically Adjusted Price-to-FCF for today is 31.35.

The historical rank and industry rank for Myriad Genetics's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

LTS:0K3W' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 6.29   Med: 18.83   Max: 57.82
Current: 30.91

During the past years, Myriad Genetics's highest Cyclically Adjusted Price-to-FCF was 57.82. The lowest was 6.29. And the median was 18.83.

LTS:0K3W's Cyclically Adjusted Price-to-FCF is ranked better than
51.56% of 64 companies
in the Medical Diagnostics & Research industry
Industry Median: 30.71 vs LTS:0K3W: 30.91

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Myriad Genetics's adjusted free cash flow per share data for the three months ended in Sep. 2024 was $-0.062. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.49 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Myriad Genetics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Myriad Genetics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myriad Genetics Cyclically Adjusted Price-to-FCF Chart

Myriad Genetics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.58 6.76 18.91 12.68 32.21

Myriad Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.32 32.21 38.21 49.63 55.19

Competitive Comparison of Myriad Genetics's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Myriad Genetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Cyclically Adjusted Price-to-FCF falls into.



Myriad Genetics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Myriad Genetics's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=15.3599/0.49
=31.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Myriad Genetics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.062/133.0289*133.0289
=-0.062

Current CPI (Sep. 2024) = 133.0289.

Myriad Genetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.618 99.070 0.830
201503 0.345 99.621 0.461
201506 0.674 100.684 0.891
201509 0.399 100.392 0.529
201512 0.691 99.792 0.921
201603 0.615 100.470 0.814
201606 0.491 101.688 0.642
201609 -0.064 101.861 -0.084
201612 0.425 101.863 0.555
201703 0.580 102.862 0.750
201706 0.515 103.349 0.663
201709 0.311 104.136 0.397
201712 0.430 104.011 0.550
201803 0.119 105.290 0.150
201806 0.632 106.317 0.791
201809 0.089 106.507 0.111
201812 0.458 105.998 0.575
201903 0.047 107.251 0.058
201906 0.402 108.070 0.495
201909 0.195 108.329 0.239
201912 -0.071 108.420 -0.087
202003 0.185 108.902 0.226
202006 0.370 108.767 0.453
202009 -0.814 109.815 -0.986
202012 -0.277 109.897 -0.335
202103 0.851 111.754 1.013
202106 -0.115 114.631 -0.133
202109 -0.519 115.734 -0.597
202112 -0.161 117.630 -0.182
202203 -0.659 121.301 -0.723
202206 -0.701 125.017 -0.746
202209 -0.254 125.227 -0.270
202212 -0.270 125.222 -0.287
202303 -0.697 127.348 -0.728
202306 -0.241 128.729 -0.249
202309 -0.484 129.860 -0.496
202312 -0.789 129.419 -0.811
202403 -0.303 131.776 -0.306
202406 -0.070 132.554 -0.070
202409 -0.062 133.029 -0.062

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Myriad Genetics  (LTS:0K3W) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Myriad Genetics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Myriad Genetics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Myriad Genetics Business Description

Traded in Other Exchanges
Address
320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Myriad Genetics Headlines

No Headlines